PCI Biotech Holding — M&A Activity 2018

Jan 18, 2018

PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company

PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company

Oslo (Norway), 18 January 2018 - PCI Biotech (OSE: PCIB), a cancer focused

biopharmaceutical company today announced that they are extending the

preclinical research collaboration with an undisclosed top-10 pharma company,

initiated in September 2015. The extended evaluation period spans over 6 months,

until the end of June 2018, and may be further extended.

The pharma company is one of the global leaders in nucleic acid therapeutics.

The aim of the extension is to further evaluate the synergistic effects of both

parties' technology platforms and to determine whether PCI Biotech's fimaNAc

technology has the potential to enhance the therapeutic effect of the partner's

nucleic acid therapeutic compounds. The companies will evaluate the data

generated in this research collaboration and explore the potential for a further

partnership based on this outcome.

Contact information:

Per Walday, CEO

pw@pcibiotech.no

Mobile: +47 917 93 429

About PCI Biotech

PCI Biotech is a biopharmaceutical company focusing on development and

commercialisation of novel therapies for the treatment of cancer through its

innovative photochemical internalisation (PCI) technology platform.  PCI is

applied to three distinct anticancer paradigms: fimaChem (enhancement of

chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction

technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics

delivery).

Photochemical internalisation induces triggered endosomal release that is used

to unlock the true potential of a wide array of therapeutic modalities. The

company's lead fimaChem programme consists of a clinical Phase I/II clinical

study in bile duct cancer, an orphan indication with a high unmet need and

without approved products.  fimaVacc applies a unique mode of action to enhance

the essential cytotoxic effect of therapeutic cancer vaccines, which works in

synergy with several other state-of-the-art vaccination technologies.  fimaNAc

utilises the endosomal release to provide intracellular delivery of nucleic

acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major

bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

PCI Biotech disclaims any obligation to update or revise any forward-looking

statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section

5 -12 of the Norwegian Securities Trading Act.